The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls
Furthermore, no other compound currently available from UK research suppliers engages all three pathways simultaneously
Another recent study, 344 which examined the impacts of another GLP-1, GIP and GCGR tri-agonist in rodents, found that treatment with this agonist decreased body weight, food intake and hyperglycaemia
When considering quality, Dr
2019;25(Suppl 2):1-75
Tailored Treatment Plans: A one-size-fits-all approach to weight loss rarely yields sustainable results